<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505492</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-535</org_study_id>
    <nct_id>NCT00505492</nct_id>
  </id_info>
  <brief_title>Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy</brief_title>
  <official_title>A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To test whether the addition of chemotherapy to radiotherapy improves the&#xD;
           progression-free survival for patients with stage I, II and IIIa malignant mixed&#xD;
           mesodermal tumor (MMMT) of the uterus.&#xD;
&#xD;
        2. To determine the acute and late toxicity profiles associated with this treatment&#xD;
           regimen.&#xD;
&#xD;
        3. To describe the effect of this treatment regimen on the patient's quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in this study will have an operation to remove their uterus, tubes, and ovaries with&#xD;
      biopsies of the omentum and lymph nodes before entering this study.&#xD;
&#xD;
      Before treatment starts, patients will have a chest x-ray, computed tomography (CT) scan,&#xD;
      blood tests, and a physical exam. Patients who have a history of hearing loss will have a&#xD;
      hearing test.&#xD;
&#xD;
      Within 8 weeks after surgery, patients will receive 5 weeks of combination radiation therapy&#xD;
      and cisplatin chemotherapy. Radiation and cisplatin will be given on Day 1 or day 2 of each&#xD;
      week followed by 4 days of radiation alone. An additional dose of radiation, directed at the&#xD;
      surface of the vagina, will be given either during the last week (Week 5) of treatment or&#xD;
      after the radiation and cisplatin chemotherapy is finished.&#xD;
&#xD;
      Three to five weeks after radiation therapy and cisplatin chemotherapy is finished, patients&#xD;
      will receive additional chemotherapy. Carboplatin and paclitaxel will be given every 28 days&#xD;
      for 4 cycles. All chemotherapy is given into the vein through a catheter (tube).&#xD;
&#xD;
      Patients will be taken off study if their disease gets worse or intolerable side effects&#xD;
      occur. Patients will be seen one month after the last cycle of chemotherapy, then every 3-4&#xD;
      months from then on for 2 years. At each visit, patients will have blood tests and a physical&#xD;
      exam. Computed tomography (CT) scans will be ordered only if it is suspected that the disease&#xD;
      has come back. All patients will be followed for a maximum of 2 years after their therapy is&#xD;
      completed.&#xD;
&#xD;
      This is an investigational study. Cisplatin, Carboplatin and Paclitaxel are FDA approved and&#xD;
      commercially available. A total of 49 patients will take part in this study. Up to 25&#xD;
      patients may be enrolled at M. D. Anderson Cancer Center in Houston, up to 12 patients will&#xD;
      be enrolled at MD Anderson Cancer Center, Orlando, and up to 12 patients will be enrolled at&#xD;
      the University of Texas Medical Branch in Galveston.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>7 Years</time_frame>
    <description>Survival defined as observed length of life from study entry until death or, for living patients, date of last contact.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Uterine Neoplasms</condition>
  <arm_group>
    <arm_group_label>Radiation + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 by vein once every 28 Days</description>
    <arm_group_label>Radiation + Chemotherapy</arm_group_label>
    <other_name>paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg/m^2 by vein (IV) Weekly Over 4 Hours</description>
    <arm_group_label>Radiation + Chemotherapy</arm_group_label>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>135 mg/m^2 by vein (IV) Once Every 28 Days</description>
    <arm_group_label>Radiation + Chemotherapy</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed malignant mixed mesodermal (MMMT) confined to&#xD;
             the pelvis (Stage IB, IC, IIA, IIB, IIIA).&#xD;
&#xD;
          -  Patients who have undergone a total abdominal hysterectomy, vaginal hysterectomy or&#xD;
             laparoscopic assisted vaginal hysterectomy and a bilateral salpino-oophorectomy (with&#xD;
             minimal surgical staging, including omental biopsy and lymph node sampling) within 8&#xD;
             weeks of study entry.&#xD;
&#xD;
          -  No known metastatic extrauterine metastases, no known gross residual disease or&#xD;
             distant metastases.&#xD;
&#xD;
          -  Women of any racial or ethnic group are eligible.&#xD;
&#xD;
          -  Zubrod performance status of &lt;/= 2.&#xD;
&#xD;
          -  Adequate bone marrow, renal and hepatic function: Hgb &gt; 10 gm/dl, ANC &gt;1.5/mm3,&#xD;
             Platelets &gt; 100,000/mcl, Creatinine &lt; 1.5 mg/%, Bilirubin &lt; 2.5 mg/dl, SGPT &lt; 2* ULN,&#xD;
             BUN &lt; 1.5* ULN.&#xD;
&#xD;
          -  No prior chemotherapy or radiation therapy for this diagnosis.&#xD;
&#xD;
          -  Estimated life expectancy of 12 weeks or greater.&#xD;
&#xD;
          -  Must sign an institutionally approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously treated malignant mixed mesodermal (MMMT) with either chemotherapy or&#xD;
             radiotherapy (XRT)/&#xD;
&#xD;
          -  Patients with gross residual disease, suspected extrapelvic or extrauterine disease or&#xD;
             distant metastatic disease (Stage IIIB, IIIC or IV).&#xD;
&#xD;
          -  History of other malignancy, with the exception of non-melanomatous skin cancer,&#xD;
             unless in complete remission and off all therapy for that disease for a minimum of 5&#xD;
             years.&#xD;
&#xD;
          -  Patients with a Zubrod performance status of 3 or greater.&#xD;
&#xD;
          -  Patients with an active systemic infection.&#xD;
&#xD;
          -  Patients with a serious intercurrent medical illness.&#xD;
&#xD;
          -  Patients with a recent (within 6 months) history of cardiac dysrhythmia, congestive&#xD;
             heart failure, unstable angina or myocardial infarction.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lois M. Ramondetta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <last_update_submitted>September 13, 2011</last_update_submitted>
  <last_update_submitted_qc>September 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Mixed Mesodermal Tumor</keyword>
  <keyword>MMMT</keyword>
  <keyword>Uterine Neoplasms</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Mixed Tumor, Mesodermal</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

